Venous Thromboembolism Following Colorectal Surgery for Suspected or Confirmed Malignancy by Sanderson, Brenton et al.
Hindawi Publishing Corporation
Thrombosis
Volume 2011, Article ID 828030, 5 pages
doi:10.1155/2011/828030
Clinical Study
VenousThromboembolism Following Colorectal Surgeryfor
S u s p e c t e do rC o n ﬁ rm e dM a l i gn a n c y
Brenton Sanderson,KerryHitos, and John P. Fletcher
Department of Surgery, University of Sydney, Westmead Hospital, Westmead, NSW 2145, Australia
Correspondence should be addressed to John P. Fletcher, johnf@med.usyd.edu.au
Received 5 November 2010; Accepted 19 April 2011
Academic Editor: Thomas Kickler
Copyright © 2011 Brenton Sanderson et al. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.
Surgery forcolorectalcancer conveys a highrisk ofvenousthromboembolism (VTE).The eﬀect ofthromboprophylactic regimens
ofvarying duration ontheincidence ofVTEwasassessedin 417patients undergoingsurgery between 2005and2009forcolorectal
cancer. Low-dose unfractionated heparin (LDUH) was used in 52.7% of patients, low-molecular-weight heparin (LMWH) in
35.3%,and10.7%received LDUHfollowedbyLMWH.Pharmacologicalprophylaxiswascontinued afterhospitalisationin31.6%.
Majorbleeding occurred in 4% of patients.The 30-day mortality rate was 1.9%. The incidence of symptomatic VTE from hospital
admissionfor surgery to 12 months after was 2.4%. There were no in-hospital VTE events. The majority of events occurred in the
three-month period after discharge, but there were VTE events up to 12 months, especially in patients with more advanced cancer
and multiple comorbidities.
1.Introduction
Major surgery conveys a signiﬁcant risk of venous throm-
boembolism (VTE), a conditionthat encompassesboth deep
vein thrombosis (DVT) and pulmonary embolism (PE). The
ﬁrst-time incidence of VTE in the general population is
approximately 100 persons per 100,000 per year [1]. VTE
is a common cause of morbidity and mortality in surgical
patients which is preventable in the majority of cases with
appropriate prophylaxis [1, 2]. There are numerous risk fac-
tors for developing VTE and, importantly, for colorectal
cancer surgery patients, include increasing age, history of
VTE, malignancy and its treatment, and surgery duration
[3–5]. The presence of these risk factors places colorectal
cancersurgery patientsat an increased risk ofVTE compared
to general surgical patients [5, 6]. A retrospective analysis
examined VTE in colorectal cancer patients, 70% of whom
underwent surgery, and found a VTE incidence of 3.1%
(2,100 patients) at two years [6]. The incidence rate was
found to decrease over the two-year period, demonstrating
the importance of VTE prophylaxis in the period after diag-
nosis and perioperatively [6]. The strongest predictors for
VTE occurrence in this patient group were found to be the
presence of metastatic disease and multiple co-morbidities
[6].
In the American College of Chest Physicians (ACCP)
evidence-based clinical practice guidelines, colorectal cancer
surgery patients are judged as having a high risk of VTE and
are recommended to receive both anticoagulant and mecha-
nical VTE prophylaxis unless contraindicated [7]. For anti-
coagulant prophylaxis, colorectal cancer surgery patients
are recommended to receive low-molecular-weight heparin
(LMWH), low-dose unfractionated heparin (LDUH) three
times daily, or fondaparinux until discharge from hospital
[7]. Mechanical prophylaxis is recommended in the form of
graduated compression stockings (GCS) and/or the use of
an intermittent pneumatic compression (IPC) device [7]. In
addition, the 2008 ACCP guidelines suggest consideration of
VTE prophylaxis with LMWH being continuedafter hospital
discharge for up to 28 days for patients who have undergone
major cancer surgery [7].
In 2009, the National Health and Medical Research
Council (NHMRC) of Australia produced evidence-based
clinical practice guidelines for the prevention of VTE to2 Thrombosis
improve the application of VTE prophylaxis recommenda-
tions in Australian hospitals [8]. These guidelines recom-
mend the appropriate use ofanticoagulant prophylaxis for at
least seven to 10 days postoperatively in the form of LMWH
or LDUH and, if contraindicated, the use of GCS [8]. The
use of extended thromboprophylaxis with LMWH for up to
28 days after colorectal cancer surgery is also recommended
for consideration [8].
The current study was undertaken to review the eﬀect of
diﬀerent types and duration of thromboprophylactic modal-
ities on VTE incidence and to evaluatethe incidence and risk
factors for bleeding complications in patients undergoing
surgery for colorectal cancer.
2.Materialsand Methods
From January 1, 2005 to December 31, 2009, 417 patients
who underwent colorectal surgery for suspected or con-
ﬁrmed malignancy were identiﬁed from the Westmead
HospitalDepartmentofSurgerydatabaseregistry. Allpatient
records were analysed retrospectively for the occurrence of
DVT and/or PE, 30-day mortality, and hospital readmission
within three months and twelve months of surgery.
From this study population, a computer-generated ran-
dom sample of 150 patients, 30 per year, was selected
using Statistical Product and Service Solutions version 16.0
(SPSS Inc., Chicago, IL, USA). The medical records of these
patients were then reviewed for the following variables:
patient demographics, diagnosis and co-morbidities, preop-
erative haemoglobin level, operative and anaesthetic details,
pre- and postoperative VTE prophylaxis, and postoperative
complications, including major bleeding.
Symptomatic DVT was conﬁrmed by documentation of
positive duplex ultrasonography for DVT and for symp-
tomatic PE by high probability ventilation perfusion lung
scan or CT pulmonary angiography. Readmission for VTE
was recorded when a patient having been discharged from
hospital was readmitted with VTE symptoms within a three-
month period with imaging conﬁrming a diagnosis of DVT
and/or PE.
Pharmacological prophylaxis was LMWH enoxaparin
(Clexane/Lovenox; Sanoﬁ-aventis, Paris, France) adminis-
tered subcutaneously (20mg or 40mg daily) preoperatively
and/or postoperatively or LDUH subcutaneously (5,000IU)
two or three times daily preoperatively and/or postop-
eratively. Pharmacological prophylaxis administration was
expected to continue for seven to 10 days according to ACCP
guidelines [7]. GCS and/or IPC devices were applied imme-
diately preoperatively and continued intraoperatively and
postoperatively. Major bleeding complications were deﬁned
as non anaemic patients preoperatively (haemoglobin >
120g/Lforfemalesand>130g/Lformales)whoexperienced
bleeding requiring transfusion of greater than two units of
blood during their hospital admission, cessation of heparin,
orreoperation[9]. Daysto ambulation was consideredas the
number of days from date of operation to the date of ﬁrst
documentation by physiotherapist or nursing staﬀ that the
patient was ambulatory.
2.1. Statistical Analysis. Data was entered into a speciﬁcally
designed Clinical Reporting Systems database version 1.1ma
(G.E.MedicalSystemPty Ltd.,Australia).Continuousdatais
givenasthemedianandinterquartilerange(IQR,rangefrom
the 25th to the 75th percentile). Continuous data groups
were compared using the two-tailed Mann Whitney U test.
Statistical signiﬁcant diﬀerences were considered at the P<
.05 level and where possible 95% conﬁdence intervals (CI)
are presented.
3.Results
3.1. Patient Characteristics. The median patient age was 67
(IQR: 58.3–76) with a male-to-female ratio of 1:1. The
median length of stay (LOS) was 10 days (IQR: 7–14),
decreasing from 13 days (IQR: 10.3–19.8) in 2005 to seven
days (IQR: 6–11) in 2009. The LOS for laparoscopic and
open procedure patients was seven days (IQR: 6–10) and
11 days (IQR: 9–15), respectively (P<. 0001). In terms
of VTE risk factors, 98% (95% CI: 94.3–99.3%) of patients
had conﬁrmed malignancy with malignant neoplasm of the
rectum being the most common site, accounting for 27.3%
(95% CI: 20.8–34.9%) of all patients. 72.7% (95% CI: 65.0–
79.2%) of patients had a cancer stage of three or higher. The
median number of co-morbidities was three (IQR: 2–4.8),
with 5.3% (95% CI: 2.7–10.2%) of patients having a history
of VTE. 44% (95% CI: 36–52%) had an American Society
of Anaesthesiology (ASA) score of three (indicating severe
systemic disease) and 47% (95% CI: 39.9–55.6%) a score of
two (mild systemic disease).
3.2. Operative and Anaesthetic Details. Anterior resection
was the most common procedure performed, accounting for
45.3% (95% CI: 37.6–53.3%) of all procedures, followed by
right hemicolectomy in 28.7% (95% CI:22.0–36.4%), total
colectomy in 8.7% (95% CI: 5.3–14.1%), and abdominoper-
ineal resection in 7.3% (95% CI: 4.1–12.7%). A further 10%
(95% CI: 6.2–15.8%) included other colorectal surgery such
as Hartmann’s procedure and left hemicolectomy. Overall,
26% (95% CI: 19.6–33.6%) of operations were performed
laparoscopically.
The median operative duration was 167 minutes (IQR:
131–210). General anaesthesia was used in 60% (95% CI:
52–67.5%) of patients and a combination of general and
neuraxial anaesthesia in 38.7% (95% CI: 31.3–46.7%). The
use ofgeneral anaesthetic only increased from 53.3% in 2005
to 83.3% in 2009, with general and neuraxial anaesthesia,
decreasing from 43.3% in 2005 to 16.7% in 2009 as shown
in Figure 1.
The median number of days to ambulation decreased
from three days (IQR: 2-3) in 2005 to 1.5 days (IQR: 1-2)
in 2009.
3.3.VTE Prophylaxis. Pharmacologicalprophylaxiswasused
in 98.7% (95% CI: 95.3–99.6%) and mechanical prophylaxis
in99.3%(95%CI:96.3–99.9%)ofpatients.LMWHwasused
in 35.3% (95% CI: 28.1–43.3%) of patients and LDUH in
52.7% (95% CI: 44.7–60.5%). LDUH followed by LMWHThrombosis 3
was used in 10.7% of patients (95% CI: 6.7–16.6%). The
pharmacologicalprophylaxisdoseregimesutilisedareshown
in Table 1.
The duration of in-hospital pharmacological VTE pro-
phylaxis decreased from 10 days (IQR: 4–12.5) in 2005 to 5.5
days (IQR: 3–8) in 2009 corresponding to decreasing length
of stay. Pharmacological prophylaxis was given to 86% (95%
CI: 79.5–90.7%) of patients postoperatively only compared
to 12.7% (95% CI: 8.3–18.9%) receiving heparin preop-
eratively and postoperatively. Median time to operation
for preoperative LMWH administration was 13hrs (IQR:
8.0–17.8hrs) and from operation for postoperatively only
administration was 8.5hrs (IQR: 5.7–23.3hrs). Median
time to operation from preoperative LDUH administration
was 17.1hrs (IQR: 12.2–24.6hrs) and from operation for
postoperatively only administration was 7hrs (IQR: 5.1–
9.3hrs). The changing pattern over ﬁve years (2005 to 2009)
in duration of pharmacological VTE prophylaxis in hospital
and after discharge, is shown in Figure 2.
ACCP and NHMRC guidelines for VTE prophylaxis rec-
ommend colorectal cancer surgery patients receive LMWH
or LDUH for at least seven to 10 days postoperatively with
consideration of extended prophylaxis for up to 28 days after
discharge [7, 8]. During hospital stay, 76% (95% CI: 68.6–
82.1%) of patients received the recommended in-hospital
VTE prophylaxis for at least seven to 10 days. For patients
with a length of stay less than seven days, 52.4% (95% CI:
32.4–71.7%) received extended prophylaxis up to 14 days
after discharge. Overall, in the period after discharge, 68.4%
(95% CI: 61.6–76.2%) of patients did not receive any VTE
prophylaxis, 25.7% (95% CI: 19.6–33.6%) received up to 14
days of VTE prophylaxis and 4.6% (95% CI: 2.3–9.3%) of
patients received VTE prophylaxis beyond 14 days and up
to 28 days after discharge. The use of VTE prophylaxis after
discharge has improved dramatically from 6.7% (95% CI:
1.9–21.3%)in 2005 to 73.3% (95% CI: 55.6–85.8%)in 2009.
In terms of VTE prophylaxis regimes on discharge, 25.3%
(95% CI: 19.1–32.9%) of patients used LMWH 40mg daily
and equal minorities of 1.3% (95% CI: 0.3–4.7%) patients
used LMWH 20mg daily, LDUH 5000IU twice daily, or
warfarin.
3.4. Major Bleeding Complications. Major bleeding compli-
cations occurred in 4% (95% CI: 1.9–8.5%) of patients,
3.3% receiving LDUH and 0.7% LMWH (70 patients who
were anaemicpreoperativelyandtwo patientswith unknown
preoperative haemoglobin were excluded from analysis).
3.5. VTE Incidence. F r o mt h et i m eo fo r i g i n a la d m i s s i o nt o
12 months after discharge, the overall incidence of VTE was
2.4% (95% CI: 1.3–4.4%). Of these patients, 75% (95% CI:
40.9–92.9%) had a TNM stage greater than three and 62.5%
(95% CI: 13.7–69.4%) did not receive VTE prophylaxis after
discharge. The median number of co-morbities in this group
was 4.5 (95% CI: 2–5.5). The proportion of VTE events at
threemonthsand at12monthsisshown inFigure3(no VTE
events occurred in hospital). DVT occurred in 1.2% (95%
CI: 0.5–2.8%) of patients overall, non fatal PE in 0.9% (95%
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Figure 1: Anaesthesia usage by year.
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Figure 2: Duration of pharmacologicalVTE prophylaxis.
CI: 0.4–2.4%), and suspected or conﬁrmed fatal PE in 0.2%
(95% CI: 0.04–1.4%). Both DVT and PE occurred in 0.5%
(95% CI: 0.1–1.7%) of patients. The median length of time
after discharge to each type of VTE event was 70 days (IQR:
67.8–202.8)for DVT,57.5 days(IQR:41–114.3)fornonfatal
PE, and 8 days (IQR: 8–8) for suspected or conﬁrmed fatal
PE. The 30-day mortality rate was 1.9% (95% CI: 1.0–3.7%)
with the causes of death listed in Table 2.
3.6. Readmission. Of the 417 patients, 19.4% (95% CI: 15.9–
23.5%) experienced at least one hospital readmission in the
three months after discharge. At 12 months after discharge,
27.6% (95% CI: 23.5–32.1%) had at least one readmission.
VTE accounted for 7.4% (95% CI: 3.4–15.2%), and 8.7%4 Thrombosis
Table 1: PharmacologicalVTE prophylaxis dose regimes.
Pharmacologicalprophylaxis dose regime % of patients %o fp a t i e n t sp o s t
discharge prophylaxis
12 month VTE
incidence (%)
Major bleeding
complications
(%)
LMWH 20mg daily 5.3 0.7 0 0
LMWH 40mg daily 30 16 1.2 0.7
LDUH 5000IU twice daily 30.7 4.7 1 1.3
LDUH 5000IU three times daily 3.3 0.7 0 0
LDUH followed by LMWH 10.7 4.7 0.2 0.7
None or inadequate LDUH 20 4 0 0.7
Table 2: 30-day mortality cause.
30-day mortality cause N %o fd e a t h s
Acute renal failure 3/8 37.5
Sepsis 3/8 37.5
Cardiac complications 2/8 25
Gastrointestinal haemorrhage 2/8 25
Pulmonary embolism 1/8 12.5
Respiratory failure 1/8 12.5
∗A given patient may have more than one cause of death.
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Figure 3: VTE incidence.
(95% CI: 4.8–15.3%) of readmissions in the ﬁrst three and
12 months, respectively.
4.Discussion
The overall incidence of VTE in patients undergoing col-
orectal surgery for suspected or conﬁrmed malignancy was
found to be 2.4% out to 12 months, with all identiﬁed VTE
events occurring following initial hospital discharge. More
than half of these VTE events (1.4%) occurred within three
months of discharge. The incidence of VTE in this study
is lower than published ﬁgures and may underestimate the
true incidence of VTE [10]. Some patients may have been
managed atanotherhospital orby theirmedical practitioner.
Colorectal cancer surgery patients have been shown to be at
signiﬁcant risk of VTE during the period after discharge and
appropriate prophylaxis is able to reduce this risk [11–13].
A meta-analysis based on three randomised controlled trials
of extended VTE prophylaxis totalling 1,104 major abdomi-
nal surgery patients demonstrated a signiﬁcant reduction in
VTE incidence at cessation of extended prophylaxis, where
5.9% of extended prophylaxis patients experienced VTE
compared to 13.6% of in-hospital only prophylaxis patients
[10]. VTE incidence was examined in two trials and at three
months was found to be 6.2% in the extended prophylaxis
groupcomparedto14.3%inthein-hospitalonlyprophylaxis
group [10]. This study also demonstrated no signiﬁcant
diﬀerence in the incidence of major or minor bleeding with
extendedprophylaxis, with 3.9%intheextendedprophylaxis
group and 3.5% in the in-hospital only prophylaxis group
[10].
The incidence of major bleeding complications found in
this study (4%) is comparable to other studies and despite
the diﬀerence in incidence of major bleeding complications
between LDUH and LMWH in this study (3.3% and 0.7%,
respectively) many studies have demonstrated no signiﬁcant
diﬀerence in risk of bleeding between LDUH and LMWH
[10, 14].
Our patients’ median length of stay decreased from 13
days (IQR: 10.3–19.8) in 2005 to 7 days (IQR: 6–11) in
2009 with patients undergoing a laparoscopic procedure
having a signiﬁcantly shorter LOS (P<. 0001). The time to
ambulation after surgery decreased by half, from a median
of three days in 2005 to one and a half days in 2009,
with earlier mobilisation likely decreasing risk of VTE.
This may be partially attributable to a decrease in the use
of combination general and neuraxial anaesthesia and an
increased useof generalanaesthesia aloneallowing forearlier
ambulation without adjunctive neuraxial anaesthesia. In
patients found to have VTE, multiple recognised risk factors
were present including advanced-stage cancer, multiple co-
morbidities, and operative duration greater than two hours
[4].Chemotherapyisasigniﬁcant risk factorforthedevelop-
ment of VTE in cancer patients and may have contributed to
the incidence of VTE after discharge in this study; however,
examination of its eﬀect was beyond the scope of this study
[5].
In the period 2005 to 2009, the median duration of in-
hospital pharmacological VTE prophylaxis fell from 10 days
in 2005 to 5.5 days in 2009, corresponding with the fall in
median LOS from 13 days in 2005 to seven days in 2009. In
contrast, the percentage of patients receiving pharmacologi-
cal VTE prophylaxis in the period after discharge increasedThrombosis 5
dramatically from 6.7% in 2005 to 73.3% in 2009, with
the main increase occurring in the period 2007-2008 which
corresponds to the introduction of interventional strategies
such as paper reminders placed in clinical notes for ordering
of post discharge pharmacological prophylaxis in this high-
risk group of patients [15].
A systematic review of strategies to improve VTE pro-
phylaxis in hospitals demonstrated that active interventions
such as electronic decision-support systems and paper-based
reminders were more eﬀective than passive dissemination
of guidelines, although the studies examined were not
adequately powered to demonstrate a statistically signiﬁcant
reduction in the incidence of VTE [16].
In conclusion, this study of colorectal surgery patients
with suspected or conﬁrmed malignancy demonstrated no
in-hospital symptomatic VTE events. While all patients re-
ceived VTE prophylaxis during admission, the occurrence
of the majority of VTE events in the three-month period
after discharge and the trend towards decreasing length of
hospital stay highlights the importance of VTE prophylaxis
in the period immediately after discharge. To minimise the
occurrence of VTE after discharge, it is imperative to educate
and support clinicians, allied health staﬀ, and patientson the
importance of VTE preventative strategies.
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